Therapy Areas: Inflammatory Diseases
Specialised Therapeutics' chronic graft-versus-host disease therapy approved in Australia
4 May 2026 - Australia-based independent biopharmaceutical company Specialised Therapeutics (ST) announced on Sunday that its NIKTIMVO (axatilimab) has been approved for use in Australia by the Therap...
Insilico's Rentosertib inhalation solution receives IND clearance to enter direct-to-lung clinical study
29 April 2026 - Insilico Medicine (HKEX:3696), a China-based, clinical-stage, generative AI-driven drug discovery company, announced on Tuesday that the inhalation solution of Rentosertib (ISM001-055)...
GSK secures US and EU fast-track designations for efimosfermin in MASH
27 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) announced on Monday that it has received Breakthrough Therapy Designation from the US Food and Drug Administration, as well as ...
FDA expands Sanofi and Regeneron's Dupixent approval to younger children with chronic spontaneous urticaria
23 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) announced late Wednesday that the US Fo...
AstraZeneca reports third positive Phase III trial for tozorakimab in COPD
20 April 2026 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (NYSE: AZN) on Monday reported positive high-level results from the Phase III MIRANDA trial, demonstrating that its IL-3...
GSK strengthens pulmonary hypertension pipeline with USD950m acquisition of 35Pharma
15 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) reported on Wednesday that it has completed the acquisition of 35Pharma Inc, a Canada-based clinical-stage biopharmaceutical co...